**TYK Medicines, Inc**

**浙江同源康醫藥股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 2410)**

# (1) RESIGNATION OF NON-EXECUTIVE DIRECTOR AND CHANGE OF AUTHORIZED REPRESENTATIVE; AND (2) PROPOSED RE-ELECTION OF DIRECTORS

## RESIGNATION OF NON-EXECUTIVE DIRECTOR AND CHANGE OF AUTHORIZED REPRESENTATIVE

The board (the "**Board**") of directors (the "**Director(s)**") of TYK Medicines, Inc (the "**Company**") announces that Dr. JIANG Mingyu ("**Dr. Jiang**") has tendered his resignation as a non-executive Director ("**NED**") with effect from August 17, 2026 in order to devote more time to his other business endeavors. Concurrent to his resignation as a NED, he will also cease to be an authorized representative of the Company ("**Authorized Representative**") under Rule 3.05 of the Rules Governing the Listing of Securities (the "**Listing Rules**") on The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**").

Dr. Jiang has confirmed that he has no claim against the Company in respect of his resignation and has no disagreement with the Board and the Company. Dr. Jiang has further confirmed that there is no matter in relation to his resignation that should be brought to the attention of the shareholders of the Company (the "**Shareholders**") and the Stock Exchange.

The Board would like to express its sincere gratitude and appreciation to Dr. Jiang for his valuable contributions to the Company during his tenure of services with the Company.

Further to Dr. Jiang's resignation, Dr. WU Yusheng has been appointed as the Authorized Representative under Rule 3.05 of the Listing Rules with effect on August 17, 2026.

## PROPOSED RE-ELECTION OF DIRECTORS

The term of office of certain Directors is about to expire and the Board resolved the proposed re-election of the following persons as the Directors for a term of three years (or until the expiration of the second session of the Board) commencing from the date of election of the proposed candidates at the upcoming extraordinary general meeting (the "**EGM**") of the Company subject to approval at the EGM from the Shareholders by ordinary resolutions.

The candidates proposed to be re-elected at the EGM shall be (i) Dr. WU Yusheng as an executive Director; (ii) Dr. LI Jun, Dr. GU Eric Hong and Mr. HE Chao as non-executive Directors; and (iii) Dr. LENG Yuting, Dr. XU Wenqing and Dr. SHEN Xiuhua as independent non-executive Directors. Details of each of their background and information required to be disclosed under Rule 13.51(2) of the Listing Rules is set out in Appendix I to this announcement.

As at the date of this announcement, save as disclosed in Appendix I, each of the proposed candidate has confirmed that: (i) he/she is not connected with any directors, senior management members, substantial Shareholders or controlling Shareholders (as defined under the Listing Rules); (ii) he/she does not hold any other positions in the Company or its subsidiaries; (iii) he/she has not held any directorships in any other listed companies whose securities are listed on any stock market in Hong Kong or overseas during the past three years; (iv) he/she does not hold or is not deemed to hold any interests in any shares or underlying shares of the Company or its associated corporations as defined under Part XV of the Securities and Futures Ordinance (Cap.571 of the Laws of Hong Kong); (v) there is no other information required to be disclosed pursuant to Rules 13.51(2)(h) to 13.51(2)(v) of the Listing Rules, nor has he/she been engaged or involved in any activities required to be disclosed under the aforesaid rules; and (vi) there are no other matters in connection with his/her re-election that shall be brought to the attention of the Shareholders or the Stock Exchange.

Each candidate for independent non-executive Director has respectively confirmed that: (i) he/she complies with all independence criteria set out in Rules 3.13(1) to (8) of the Listing Rules; (ii) he/she has no past or present financial or other interests in the business of the Company or its subsidiaries and no connection with any core connected persons (as defined in the Listing Rules) of the Company; and (iii) there are no other factors that may impair his/her independence at the time of re-election. The Nomination Committee of the Board has assessed and reviewed the independence of each candidate for independent non-executive Director and considers that each of candidates for independent non-executive Director has satisfied the independence requirements.

Upon the approval of the ordinary resolution in respect of the re-election of Directors by the Shareholders at the EGM, the Company shall renew service contracts and/or appointment letter with each Director.

A circular containing, among other things, further details of the proposed re-election of Directors will be despatched to the Shareholders in due course.

By Order of the Board
**TYK Medicines, Inc**
**(浙江同源康醫藥股份有限公司)**
**Dr. WU Yusheng**
*Chairman, Executive Director and Chief Executive Officer*

Hong Kong, August 17, 2026

*As at the date of this announcement, the Board comprises Dr. WU Yusheng as executive Director; Dr. LI Jun, Dr. GU Eric Hong, Mr. HE Chao and Dr. ZHU Xiangyang as non-executive Directors; and Dr. LENG Yuting, Dr. XU Wenqing, Dr. SHEN Xiuhua and Mr. JIANG Xiaolin as independent non-executive Directors.*

## APPENDIX I – BIOGRAPHICAL DETAILS OF THE DIRECTOR CANDIDATES

### Dr. WU Yusheng

Dr. WU Yusheng (吳豫生), aged 62, is the chairperson of our Board, our executive Director and chief executive officer. He founded our Group in November 2017, and has served as a Director and the chief executive officer of our Company since then and was re-designated as an executive Director on January 17, 2024. He is primarily responsible for overseeing the overall management, business operation, and strategies of our Group.

Dr. Wu has more than 26 years of experience in biomedical research and management. He conducted research at California Institute of Technology. From July 1996 to February 2009, he worked at Schering-Plough Corporation, a pharmaceutical company principally engaged in new drug development with last position as senior principal scientist, where he was primarily responsible for novel drug discovery such as for thrombosis, obesity and Alzheimer's disease. From February 2011 to October 2017, he served as the chairman of the board of directors and chief executive officer at Tetranov Pharmaceutical, a company used to be primarily engaged in providing customized pharmaceutical intermediates synthesis services where he was primarily responsible for its overall operations. Since December 2020, Dr. Wu has served as an independent non-executive Director of Shanghai Tenry Pharmaceutical Co., Ltd. (上海騰瑞製藥股份有限公司), a pharmaceutical company principally engaged in research, development and commercialization of biological drugs, covering chemical raw materials and oral solid preparations, with a focus on treatment of deep burn wound and chronic ulcer wound, where he has been primarily responsible for providing independent advice and judgment to the board of directors of the company.

In addition to roles in our Group, Dr. Wu is also currently an executive Director at LeadMed (Zhejiang) Medical Technology Co., Ltd. (浙江藥領醫藥科技有限公司), an executive Director at LeadMed (Zhengzhou) Medical Technology Co., Ltd. (鄭州藥領醫藥科技有限公司) and chairman of the board of directors of Zhejiang SynthonTech Pharmaceutical Co., Ltd. (浙江雅辰藥物科技股份有限公司).

Dr. Wu obtained his bachelor's degree in organic chemistry from Zhengzhou University (鄭州大學) in Henan in July 1985. Dr. Wu further obtained his doctor's degree in organic chemistry from Iowa State University of Science and Technology in Iowa in December 1993. Dr. Wu has also authored more than 120 scientific publications in leading chemistry and medicinal chemistry journals and has been granted more than 40 granted patents.

Dr. Wu obtained various awards during his professional career, including the New Jersey Minority Award from the Plainfield and Metuchen-Edison YMCA in 2004, and the 2006 President's Award for Discovery from Schering-Plough Research Institute. Further, Dr. Wu has been a "State Specially Recruited Expert" (國家特聘專家) as conferred by the Ministry of Human Resources and Social Security of the PRC (中華人民共和國人力資源和社會保障部) since 2013.

It is proposed that Dr. WU Yusheng will not receive any remuneration for serving as an executive Director. As of the date of this announcement, Dr. WU Yusheng is interested in 123,466,000 H Shares through interest in controlled corporations.

**Dr. LI Jun**

Dr. LI Jun (李鈞), aged 63, is our non-executive Director. He joined our Group as our vice president and chief scientific officer in June 2018 and served as our vice president and chief scientific officer until May 2021. He has served as a Director since January 2021. He was re-designated as a non-executive Director on January 17, 2024. He is primarily responsible for providing strategic advice on the development of our Group.

Dr. Li has over 24 years of experience in pharmaceutical research and investments. Dr. Li was a research scientist and group leader at the Institute of Materia Medica, Chinese Academy of Medical Sciences (中國醫學科學院藥物研究所), where he was involved in setting up the PRC's first doping control laboratory accredited by the International Olympic Committee. Dr. Li was a research scientist at Vion Pharmaceuticals, Inc., a biopharmaceutical company specializing in cancer treatment technologies, where he was involved in the development of the novel anti-cancer agent Triapine (currently conducting Phase III clinical trial). From September 1997, he worked for over 20 years as a principal scientist and program leader at Bristol-Myers Squibb Co., USA, a company principally engaged in the R&D and sales of pharmaceutical products, where his last position was principal scientist and where he was primarily responsible for new drug discovery, among which, one is currently undergoing Phase III clinical trial. Since June 2021, Dr. Li has been a scientific advisor engaged by HCA (Shanghai) Consulting Co., Ltd. (known as "Morningside Ventures" (晨興創投)).

Dr. Li obtained his bachelor's degree in applied chemistry from the University of Science and Technology of China (中國科學技術大學) in Hefei in July 1985 and his master of science from the Chinese Academy of Sciences (中國科學院) in Beijing in July 1988. Dr. Li further obtained his doctor's degree in organic chemistry from Iowa State University of Science and Technology in August 1994. Dr. Li was a post-doctoral associate at Cornell University in New York from August 1994 to July 1997.

Dr. Li co-authored over 50 peer-reviewed research papers and has been granted more than 50 U.S. or Patent Cooperation Treaty (PCT) patents. Dr. Li obtained various awards during his professional career, including the PRC "First Prize of the State Scientific and Technological Progress Award" (國家科學技術進步一等獎) from the national government of the PRC, the "Special Prize" of the China Association for Instrumental Analysis (CAIA) (中國分析測試協會特等獎獲得者), along with two "Molecule of the Year" awards and a "Chemistry Leadership Award" from Bristol Myers Squibb Co., USA.

It is proposed that Dr. LI Jun will not receive any remuneration for serving as a non-executive Director.

**Dr. GU Eric Hong**

Dr. GU Eric Hong (顧虹), aged 60, is our non-executive Director. He joined our Group in November 2017 and has served as a Director since then. He was re-designated as a non-executive Director on January 17, 2024. He is primarily responsible for providing strategic advice on the development of our Group.

Dr. Gu has extensive experience in the pharmaceutical industry. Prior to joining our Group, he worked at Mallinckrodt Pharmaceuticals plc (formerly known as Mallinckrodt Inc.), a company engaged in R&D of drugs for autoimmune diseases and other diseases. He also worked at Zhejiang Huahai Pharmaceutical Co., Ltd. (浙江華海藥業股份有限公司) ("**Zhejiang Huahai**"), a company principally engaged in sales of active pharmaceutical ingredient ("**API**"), sales of finished drugs, technical services, and import and export.

Since December 2020, he has been a director and the general manager of Shanghai Aobo Pharmtech, Inc., Ltd. (上海奧博生物醫藥股份有限公司) ("**Shanghai Aobo**"), a company primarily engaged in the production and R&D of API. He has also been the general manager of Aobo Biotechnology Hubei Co., Ltd. (奧博生物醫藥科技湖北有限責任公司), a subsidiary of Shanghai Aobo, since September 2022 and a director of Hubei Sai'ao BioPharm Co., Ltd. (湖北賽奧生物製藥有限公司) ("**Hubei Sai'ao**"), a joint venture of Zhejiang Huahai and Shanghai Aobo, since May 2021.

Dr. Gu obtained his bachelor's degree from Fudan University (復旦大學) in Shanghai in 1987 and he further obtained his doctor's degree in chemistry from the University of Missouri-St. Louis in Missouri in January 1996. Further, Dr. Gu obtained his master's degree in business administration from the University of Washington in Washington in July 2004. Since July 2017, he has been certified as a professor-level senior engineer in drug development by the Zhejiang Provincial Department of Human Resources and Social Security (浙江省人力資源和社會保障廳).

It is proposed that Dr. GU Eric Hong will not receive any remuneration for serving as a non-executive Director. As of the date of this announcement, Dr. GU Eric Hong is interested in 8,010,000 H Shares through interest in controlled corporations.

**Mr. HE Chao**

Mr. HE Chao (何超), aged 45, is our non-executive Director. He joined our Group in June 2022 and has served as a Director since then. He was re-designated as a non-executive Director on January 17, 2024. He is primarily responsible for providing strategic advice on the development of our Group.

Mr. He has approximately 12 years of experience in investment and finance. From July 2011 to April 2015, he successively served as a business director, branch general manager, and partner of Kunwu Jiuding Investment Management Co., Ltd. (昆吾九鼎投資管理有限公司), an equity investment company. He has been working at Beijing Huge Capital Management Co., Ltd. (北京融辰厚紀投資管理有限公司), an equity investment company, as the general manager since July 2015 and as an executive Director since February 2017 where he has been primarily responsible for overall strategy and development.

Mr. He obtained his master's degree in business administration from Peking University in Beijing in June 2011.

It is proposed that Mr. HE Chao will not receive any remuneration for serving as a non-executive Director. As of the date of this announcement, Mr. HE Chao is interested in 19,404,654 H Shares through interest in controlled corporations.

**Dr. LENG Yuting**

Dr. LENG Yuting (冷瑜婷), aged 42, is our independent non-executive Director. She was appointed as an independent non-executive Director on January 17, 2024. She is responsible for providing independent advice and judgment to our Board.

Dr. Leng has more than 13 years of experience in organic chemistry research and in management. From July 2011 to March 2012, Dr. Leng was a research secretary at the College of Chemistry at Zhengzhou University (鄭州大學化學學院). From April 2012 to September 2018, she served as a chemistry teacher and academic secretary at the College of Chemistry at Zhengzhou University (鄭州大學化學學院). From October 2018 to December 2019, Dr. Leng was a visiting scholar at Harvard Medical School and the Massachusetts General Hospital under the Visiting Scholar Program of the China Scholarship Council. From April 2012 to December 2023, Dr. Leng has been a lecturer at the College of Chemistry at Zhengzhou University (鄭州大學化學學院), where she is primarily responsible for teaching and conducting research. Since January 2024, Dr. Leng has served as an associate professor at the College of Chemistry at Zhengzhou University (鄭州大學化學學院), and has been long engaged in teaching and scientific research work.

Dr. Leng obtained her bachelor's degree of science in chemistry from Zhoukou Normal University (周口師範學院) in Henan in July 2006. She further obtained her doctor's degree in organic chemistry from Zhengzhou University (鄭州大學) in Henan in July 2011. Since December 2016, she was appointed as a postdoctoral researcher in medicinal chemistry at Zhengzhou University (鄭州大學) in Henan. Since April 2012, she has been certified as an intermediate university lecturer by the Henan Provincial Department of Human Resources and Social Security (河南省人力資源和社會保障廳). Since January 2024, Dr. LENG Yuting has been awarded the Associate Professor Qualification Certificate accredited by Zhengzhou University.

It is proposed that Dr. LENG Yuting shall receive a remuneration of RMB12,000 per month (before tax) for services as an independent non-executive Director.

**Dr. XU Wenqing**

Dr. XU Wenqing (許文青), aged 61, is our independent non-executive Director. He was appointed as an independent non-executive Director on January 17, 2024. He is responsible for providing independent advice and judgment to our Board.

Dr. Xu has over 16 years of experience in teaching and academia. Prior to joining our Group, he conducted research for Harvard Medical School. From July 2009 to August 2019, Dr. Xu was a tenured full professor at the University of Washington School of Medicine. Prior to joining our Group, he was also director of the National Facility for Protein Science in Shanghai, Chinese Academy of Sciences (中國科學院國家蛋白質科學研究(上海)設施), which was involved in launching the Protein Data Bank China, an associate member of the Worldwide Protein Data Bank which manages the 3D structure archive of proteins, nucleic acids and complex assemblies. Since August 2019, he has been a tenured full professor at Shanghai Tech University (上海科技大學).

Dr. Xu obtained his doctor's degree in biology from the Massachusetts Institute of Technology in Massachusetts in September 1995. Dr. Xu received the Investigator's Award in the pathogenesis of infectious disease from the Burroughs Wellcome Fund in 2003.

It is proposed that Dr. XU Wenqing shall receive a remuneration of RMB12,000 per month (before tax) for services as an independent non-executive Director.

**Dr. SHEN Xiuhua**

Dr. SHEN Xiuhua (沈秀華), aged 54, is our independent non-executive Director. She was appointed as an independent non-executive Director on January 17, 2024. She is responsible for providing independent advice and judgment to our Board.

Dr. Shen has approximately 30 years of experience in teaching and academia. Since August 1995, Dr. Shen consecutively worked as a teaching assistant in the Department of Pathology of the School of Medicine, a lecturer, an associate professor and currently a professor in the Department of Nutrition of the School of Medicine at Shanghai Jiao Tong University (上海交通大學). From September 2007 to February 2008, she was a visiting scholar at the Division of Nutritional Sciences at Cornell University. From November 2013 to October 2014, she was a visiting scholar at Harvard University.

Dr. Shen obtained her bachelor's degree in clinical medicine (medical nutrition) and her master's degree in medicine, with a major in nutrition and food hygiene, from Shanghai Jiao Tong University (上海交通大學) in Shanghai in July 1995 and June 2001, respectively. Dr. Shen further obtained her doctor's degree in pediatrics from Shanghai Jiao Tong University (上海交通大學) in Shanghai in July 2007.

It is proposed that Dr. SHEN Xiuhua shall receive a remuneration of RMB12,000 per month (before tax) for services as an independent non-executive Director.